Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Neurocrine Biosciences
Patent issued for proprietary compound for treatment of insomnia
May 14th, 2003
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has been issued U.S. Patent No. 6,544,999 (the '999 patent) covering a stable polymorph of its proprietary compound indiplon for the treatment of insomnia. The '999 patent will provide Neurocrine with patent protection for this important crystalline form of indiplon until the year 2020. "This new patent complements the patent portfolio which we are developing around this important product for the treatment of insomnia. We have previously received patents covering different synthetic schemes for the synthesis of indiplon, the modified release formulation of indiplon, and methods of making and converting...
Source: Biotech Week (2003-05-14)
|
